Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study
Objective: Our aim was to analyze the effectiveness of safinamide on sleep in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.
Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial
Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan
Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study
Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease
Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…Combined therapy VS only levodopa therapy in a 5-years follow up cohort
Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients
Objective: Patients suffering from Parkinson’s disease experience various motor and non-motor symptoms. Within the range of non-motor symptoms depression is reported as high as in…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »